| abstract |
The present invention provides bispecific antibodies, it includes be incorporated into the first binding structural domain of EGFR and be incorporated into the second binding structural domain of PD-1, wherein, the antibody or its antigen-binding fragment are the forms in the group as composed by the oligomer of single-chain antibody (scFv), double antibody and above-mentioned form.The present invention also provides the amino acid sequence of antibody of the present invention, clone or expression vector, host cell and for expressing or the method for separation antibody.Additionally provide the therapeutic combination comprising antibody of the present invention.The present invention also provides the methods with bispecific antibody treating cancer and other diseases. |